News in brief

Aarti Drugs considers formulations driven plant acqusition

Aarti Drugs considers formulations driven plant acqusition

Aarti Drugs has said it is considering buying an unnamed manufacturer in Himachal Pradesh, India to expand its drug formulations business

The Mumbai-based drugmaker told the BSE about the potential takeover earlier today. The firm explained that it “has considered a proposal to acquire an undertaking/Company at Baddi in Himachal Pradesh to cater its existing business of Toll [contract] manufacturing of formulations as an initiative to have its own facilities for this business subject to necessary diligences and approval processes.”

Aarti operates two production facilities - in Tarapur, Maharashtra and Sarigam, Gujarat – at which it produces more than 50 bulk active pharmaceutical ingredients (API), several pharmaceutical intermediates and a range of speciality chemicals.

Details of the potential acquisition target were not provided.

Related News

Some patients surveyed preferred taking effervescent medicines. (Picture: Raymond Gilford/Flickr)

A bitter pill to swallow: young people dislike tablets more than old

Aarti banned from exporting drugs to US

Aarti says US FDA has not detailed GMP problems that earned it an import ban

Hospira: Orchid debt restructuring plan brings deal closer

Hospira edges closer to completion of Orchid API deal in India

Strike Ends at Shasun API Plant but Share Price Takes Hit

Strike Ends at Shasun API Plant but Share Price Takes Hit

Mitsui confirms increased investment in Arch

Mitsui confirms increased Arch Pharmalabs investment; wants to build API biz

Related Products

See more related products